Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Investor type Micro VC
Founders Patrick Chung


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 61
Average round size
The average size of a deal this fund participated in
Portfolio companies 38
Rounds per year 5.55
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 7
Key employees 2
Stages of investment
Early Stage Venture

Areas of investment

  • Software
  • Information Technology
  • Health Care
  • Artificial Intelligence
  • FinTech

Xfund appeared to be the VC, which was created in 2012. The company was established in North America in United States. The leading representative office of defined VC is situated in the Palo Alto.

The higher amount of exits for fund were in 2018. When the investment is from Xfund the average startup value is 500 millions - 1 billion dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this Xfund performs on 21 percentage points less the average number of lead investments. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year.

The fund was created by Patrick Chung. Besides them, we counted 2 critical employees of this fund in our database.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Xfund, startups are often financed by New Enterprise Associates, Kleiner Perkins, Uncork Capital. The meaningful sponsors for the fund in investment in the same round are Experiment Fund, Kleiner Perkins, Breyer Capital. In the next rounds fund is usually obtained by New Enterprise Associates, Kleiner Perkins, Workday Ventures.

Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Analytics, Artificial Intelligence. Among the most popular portfolio startups of the fund, we may highlight 23andMe, Guideline, Inc., kea. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Xfund:
Typical Co-investors
Xfund is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Xfund:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ADT Commercial Boca Raton, Florida, United States
Ever Sunny China, Hong Kong, Hong Kong Island
Foshan Damu Touzi China, Foshan, Guangdong Province
Honeycomb Investment Trust England, London, United Kingdom
Huadao Investment Management China, Jiangsu, Xuzhou
MILI PICTURES China, Shanghai
Mount Kellett Capital Management New York, New York, United States
Nanjing Shengshi Yangzi Fund Investment Management China, Jiangsu, Nanjing
Netangels France, Marseille, Provence-Alpes-Cote d'Azur
Now Capital Delhi, India, New Delhi
One Earth Capital California, Felton, United States
Pathway Bioventures Chicago, Illinois, United States
Pinnacle Enterprise Fund -
Platform Capital Colorado, Denver, United States
PR Times Japan, Tokyo
RAAD Broadcasting Corp Bayonne, New Jersey, United States
Sixers Innovation Lab Pennsylvania, Philadelphia, United States
Vivex Capital Group Mazowieckie, Poland, Warsaw
Zweben Family Revocable Trust -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Financial Services
$20M16 Aug 2022 San Francisco, California, United States


$6M21 Jun 2022 San Francisco, California, United States

$7M15 Jun 2022 New York, New York, United States

Forma Ai

Artificial Intelligence
Information Services
Information Technology
$45M17 May 2022 Old Toronto, Ontario, Canada


$6M13 Dec 2021 San Francisco, California, United States


Information Services
Information Technology
Management Consulting
Market Research
Product Research
$32M08 Dec 2021 New York, New York, United States

Sirona Medical

Artificial Intelligence
Health Care
Health Diagnostics
$40M09 Nov 2021 San Francisco, California, United States


Higher Education
Professional Networking
$11M03 Nov 2021 Waterloo, Ontario, Canada


Financial Services
$5M12 Oct 2021 San Francisco, California, United States
Prive Raises $1.7M in Pre-Seed Funding

– Prive is a San Francisco, CA-based eCommerce subscriptions platform.
– The company raised $1.7M in pre-seed financing.
– The round was led by Xfund and Bling Capital, with participation from Defy Partners, Halogen Ventures, Base Case Capital, and current senior Uber executives.

ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics

– ImmuneID, Inc. has raised $50m in Series A financing.
– The round was led by new investor Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management.
– All existing investors participated in the financing, including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others.
– Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Xfund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: